申请人:Hoechst Aktiengesellschaft
公开号:US04940790A1
公开(公告)日:1990-07-10
Novel 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6H-1,3,4-thiadiazines of the general formula I ##STR1## in which R.sup.1 =C.sub.1 -C.sub.4 -alkyl, R.sup.2 =H or C.sub.1 -C.sub.3 -alkyl R.sup.3 and R.sup.4 =independently of one another, optionally substituted and optionally O- or S-interrupted alkyl, alkenyl or alkynyl groups, it being possible for one of the two radicals to also be H, or R.sup.3 +R.sup.4 together with the nitrogen atom to which they are bound, may denote an optionally substituted 4- to 7-membered ring which optionally contains a further heteroatom (O, S or N), and the physiologically acceptable acid-addition salts thereof. The compounds are primarily suitable for prevention and treatment of inflammatory--in particular inflammatory rheumatic--disorders and/or pain.
通式I中的新型化合物为5-(3-烷基-5-叔丁基-4-羟基苯基)-2-氨基-6H-1,3,4-噻二嗪,其中R.sup.1 =C.sub.1 -C.sub.4-烷基,R.sup.2 =H或C.sub.1 -C.sub.3-烷基,R.sup.3和R.sup.4 =独立地,可选择性地取代和可选择地O-或S-中断的烷基,烯基或炔基基团,其中两个基团中的一个也可能是H,或者R.sup.3 + R.sup.4与它们结合的氮原子一起,可能表示一个可选择性取代的4-至7-环,该环可以选择性地包含进一步的杂原子(O,S或N),以及其生理上可接受的酸加成盐。这些化合物主要适用于预防和治疗炎症 - 特别是炎症性风湿性疾病和/或疼痛。